These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 11443549)

  • 1. Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.
    Greijer AE; Verschuuren EA; Dekkers CA; Adriaanse HM; van der Bij W; The TH; Middeldorp JM
    J Infect Dis; 2001 Aug; 184(3):247-55. PubMed ID: 11443549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective assessment of cytomegalovirus immune evasion gene transcription profiles in transplant patients with cytomegalovirus infection.
    Humar A; Kumar D; Gray M; Moussa G; Venkataraman S; Kumar R; Tipples GA
    Transplantation; 2007 May; 83(9):1200-6. PubMed ID: 17496536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct quantification of human cytomegalovirus immediate-early and late mRNA levels in blood of lung transplant recipients by competitive nucleic acid sequence-based amplification.
    Greijer AE; Verschuuren EA; Harmsen MC; Dekkers CA; Adriaanse HM; The TH; Middeldorp JM
    J Clin Microbiol; 2001 Jan; 39(1):251-9. PubMed ID: 11136779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative competitive NASBA for measuring mRNA expression levels of the immediate early 1, late pp67, and immune evasion genes US3, US6 and US11 in cells infected with human cytomegalovirus.
    Greijer AE; Adriaanse HM; Kahl M; Tacken NM; Oldenburg N; Sijlmans A; van de Crommert JM; Dekkers CA; Sillekens PT; Middeldorp JM
    J Virol Methods; 2001 Aug; 96(2):133-47. PubMed ID: 11445144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset and duration of cytomegalovirus immediate early 1 mRNA expression in the blood of renal transplant recipients.
    Goossens VJ; Christiaans MH; Blok MJ; Terporten PH; Sillekens P; Lukacsi A; Van Hooff JP; Bruggeman CA
    J Med Virol; 2004 Jan; 72(1):94-101. PubMed ID: 14635016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of reverse transcription polymerase chain reaction in the detection of human cytomegalovirus gene transcripts in thoracic organ transplant recipients.
    Lam KM; Oldenburg N; Khan MA; Gaylore V; Mikhail GW; Strouhal PD; Middeldorp JM; Banner N; Yacoub M
    J Heart Lung Transplant; 1998 Jun; 17(6):555-65. PubMed ID: 9662090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of US28 gene expression during active human cytomegalovirus infection in lung-transplant recipients.
    Boomker JM; Verschuuren EA; Brinker MG; de Leij LF; The TH; Harmsen MC
    J Infect Dis; 2006 Jun; 193(11):1552-6. PubMed ID: 16652284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the R1 element on expression of the US3 and US6 immune evasion genes of human cytomegalovirus.
    Bullock GC; Lashmit PE; Stinski MF
    Virology; 2001 Sep; 288(1):164-74. PubMed ID: 11543669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCMV pp67-mRNA detection by nucleic acid sequence-based amplification in renal transplant patients.
    Merlino C; Bergallo M; Gregori G; Sinesi F; Bollero C; Cavallo R
    New Microbiol; 2002 Jan; 25(1):1-8. PubMed ID: 11837384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification.
    Gerna G; Baldanti F; Middeldorp JM; Furione M; Zavattoni M; Lilleri D; Revello MG
    J Clin Microbiol; 1999 Apr; 37(4):902-11. PubMed ID: 10074499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of active cytomegalovirus infection by analysis of immediate-early, early and late transcripts in peripheral blood cells of immunodeficient patients.
    Meyer T; Reischl U; Wolf H; Schüller C; Arndt R
    Mol Cell Probes; 1994 Aug; 8(4):261-71. PubMed ID: 7870068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection.
    Mengoli C; Cusinato R; Biasolo MA; Cesaro S; Parolin C; Palù G
    J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced levels of IE2 gene expression and shutdown of early and late viral genes during latent infection of the glioblastoma cell line U138-MG with selectable recombinants of human cytomegalovirus.
    Wolff D; Sinzger C; Drescher P; Jahn G; Plachter B
    Virology; 1994 Oct; 204(1):101-13. PubMed ID: 8091645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a quantitative-competitive PCR for quantification of human cytomegalovirus load and comparison with antigenaemia, viraemia and pp67 RNA detection by nucleic acid sequence-based amplification.
    Bergallo M; Costa C; Tarallo S; Daniele R; Merlino C; Segoloni GP; Negro Ponzi A; Cavallo R
    Panminerva Med; 2006 Jun; 48(2):119-27. PubMed ID: 16953149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
    Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
    Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding.
    Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F
    J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UL40 human cytomegalovirus variability evolution patterns over time in renal transplant recipients.
    Garrigue I; Faure-Della Corte M; Magnin N; Recordon-Pinson P; Couzi L; Lebrette ME; Schrive MH; Roncin L; Taupin JL; Déchanet-Merville J; Fleury H; Lafon ME
    Transplantation; 2008 Sep; 86(6):826-35. PubMed ID: 18813108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of UL18, UL40, UL111a and US3 immunomodulatory genes among human cytomegalovirus clinical isolates from renal transplant recipients.
    Garrigue I; Corte MF; Magnin N; Couzi L; Capdepont S; Rio C; Merville P; Dechanet-Merville J; Fleury H; Lafon ME
    J Clin Virol; 2007 Oct; 40(2):120-8. PubMed ID: 17827058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.